Provide safe peri-operative care for gynaecological surgery, including assessment, consent, thromboprophylaxis and enhanced recovery

In one line

Safe gynaecological surgery is a system, not a single skill: the operation itself is only the middle of a chain that runs from honest risk assessment and Montgomery-standard consent, through a checklist-disciplined theatre with timed antibiotic and risk-stratified VTE prophylaxis, into an enhanced-recovery pathway that gets the patient eating, mobile and home — and the consultant's job is to make every link in that chain deliberate rather than reflexive.

Performing the procedure is the lesser challenge; keeping the patient safe around it is the harder one. Complications are overwhelmingly prevented before the knife touches skin — by selecting and optimising the right patient, by disclosing risk the way the law now requires, and by hard-wiring the prophylaxis that the evidence has settled.

Mechanism & pathophysiology

Perioperative care rests on the physiology that makes surgery dangerous. Three overlapping mechanisms account for most of what is done around an operation.

The surgical stress response. Tissue injury, fasting, pain and anxiety trigger a stereotyped neuroendocrine and inflammatory cascade. Afferent nociceptive and inflammatory signals drive the hypothalamic–pituitary–adrenal axis (cortisol, ACTH) and the sympathetic nervous system (catecholamines), while damaged tissue releases cytokines (IL-6, TNF-α, IL-1). The downstream state is catabolic and pro-inflammatory: insulin resistance (functional diabetes even in non-diabetics), sodium and water retention, protein breakdown, immune suppression and a hypercoagulable shift. This matters because the response is modifiable. Almost every enhanced-recovery component — not starving the gut, carbohydrate loading, regional/opioid-sparing analgesia, minimal-access surgery, euvolaemia, early feeding — is an intervention that blunts one arm of this response. Reframed that way, enhanced recovery is not a hotel-comfort programme; it is the deliberate attenuation of a maladaptive stress physiology — which is why it works.

Virchow's triad and surgical VTE. Venous thromboembolism is the perioperative death you are most often blamed for missing, and its mechanism is Virchow's three pillars, every one of which surgery aggravates. Stasis: anaesthesia abolishes the calf-muscle pump, the patient is immobile on the table and in bed, and pelvic surgery and a gravid-sized uterus mechanically compress pelvic veins. Endothelial injury: pelvic dissection, retraction and energy devices directly damage vessel walls. Hypercoagulability: the stress response itself raises fibrinogen and clotting factors and suppresses fibrinolysis, and malignancy adds tissue-factor-driven, cytokine-mediated procoagulant activity — which is exactly why cancer surgery sits in a higher risk tier than benign surgery of identical magnitude. The triad is the through-line that explains both who needs thromboprophylaxis (the more boxes a patient ticks, the higher the tier) and which prophylaxis you reach for (mechanical methods attack stasis; pharmacological methods attack hypercoagulability; you frequently need both).

The infection mechanism. Surgical site infection follows when an inoculum of bacteria at the wound exceeds host defences during the decisive window — the few hours around incision and closure when the wound is open and the haematoma/clot is colonisable. The single most important deduction from that mechanism is timing: a tissue antibiotic concentration above the minimum inhibitory concentration must already be present at incision, not started afterwards, which is the entire rationale for giving prophylaxis in the hour before the knife rather than in recovery. Prolonging antibiotics for days afterwards does not extend that window of benefit; it only selects for resistance.

With the physiology in place, each downstream decision stops being a memorised rule and becomes a consequence.

Assessment

The pre-operative assessment exists to answer two questions: is the planned operation the right one for this patient now, and what must I fix or mitigate before I expose her to it. Work it as systematically as a booking clinic.

• Risk stratification and functional capacity. Anchor the global risk in the ASA physical-status class and, more usefully, in functional capacity — can she climb two flights of stairs or do equivalent ~4 MET activity without limiting symptoms? Poor or unassessable functional capacity in major surgery is the trigger for cardiopulmonary referral, not a reflex battery of tests. Apply NICE NG45 to preoperative testing: investigations are targeted to the surgery grade and comorbidity, not ordered routinely — a fit woman for minor day surgery needs essentially none.
• Cardiac risk. Identify active cardiac conditions (unstable angina, decompensated heart failure, significant arrhythmia, severe valve disease) that mandate optimisation or postponement. For stable disease, the combination of surgical magnitude and functional capacity drives the decision; a resting ECG and focused assessment usually suffice for intermediate-risk gynaecological surgery.
• Anaemia — correct it before, not transfuse around it. Preoperative anaemia independently predicts transfusion, infection, longer stay and death, and it is common in the SA gynaecology population (heavy menstrual bleeding, fibroids, malignancy, iron deficiency, HIV). The principle is to diagnose and treat the anaemia in clinic — iron (oral, or intravenous where time is short or oral is failing) for iron deficiency — rather than accept a low haemoglobin and plan to transfuse perioperatively. Patient blood management starts weeks before the list.
• Diabetes and glycaemia. Assess control (HbA1c), plan the perioperative regimen, schedule the patient early on the list, and target reasonable glycaemia — surgical hyperglycaemia worsens infection and the stress response amplifies it. Poor control is a reason to optimise, not a reason that fixes itself on the day.
• Smoking. Smoking impairs wound healing and oxygenation and raises pulmonary and wound complications; even short-interval cessation before surgery helps, and the pre-op clinic is a cessation opportunity, not just a risk-noting exercise.
• Frailty, not age. In the older woman, frailty (assessed with a tool such as the Clinical Frailty Scale) predicts outcome far better than chronological age. A frail patient warrants a frank conversation about goals, a tailored (often less radical) plan and proactive geriatric/anaesthetic input.
• The SA host factors. Test for and manage HIV (and optimise ART), screen for and treat anaemia and undernutrition, and remember TB and the realities of access — a patient who must travel far for follow-up needs a plan that does not assume easy return.

The assessment is not a form; it is the moment you decide what to fix. With the patient selected and optimised, the next obligation is consent — and that has changed.

Consent — the Montgomery standard and the SA frame

The law of consent has shifted from what a reasonable doctor would disclose to what a reasonable patient would want to know, and a consultant must be able to state the standard precisely.

Montgomery v Lanarkshire Health Board [2015] UKSC 11 replaced the old Bolam/Sidaway "responsible body of doctors" test with the material-risk standard. A risk is material if a reasonable person in the patient's position would be likely to attach significance to it, or the doctor is or should reasonably be aware that this particular patient would attach significance to it. Two consequences follow. First, materiality is not a fixed percentage — a small numerical risk of a consequence the patient would dread (a young woman's risk to fertility, a singer's risk to her voice) can be material, while a larger risk of a trivial outcome may not be. Second, consent is a dialogue: the duty is to discuss the material risks of the proposed procedure and the reasonable alternatives (including conservative management and doing nothing), tailored to this woman's circumstances, values and questions — not to recite a generic list at her. Montgomery is a UK judgment, but it is the standard SA medicolegal teaching has adopted and the one SA practice is held to.

The South African statutory frame sits underneath it. The National Health Act 61 of 2003 requires that a user be informed of her health status, the range of diagnostic and treatment options, and the benefits, risks, costs and consequences of each, in a language and manner she understands — a statutory expression of the same patient-centred principle. HPCSA ethical guidance on informed consent reinforces capacity, voluntariness and disclosure. For the surgical patient this means consent obtained by someone able to perform or properly describe the procedure, ideally not minutes before in the anaesthetic room; documentation of the specific material risks discussed (not a tick-box); and explicit recording of alternatives offered. Special situations recur in SA practice: the patient who lacks capacity (consent in her best interests under the Act, involve a proxy), the minor (capacity-based consent thresholds under the Children's Act for the patient herself), and the woman declining a recommended intervention (her informed refusal is her right). The defensible documentary standard is simple: what I told her, in what terms, what she asked, what she chose.

With the patient consented, attention moves to the theatre, where the next safeguard is structural rather than clinical.

Management

Organise perioperative safety as before theatre → in theatre → after theatre, and treat each prophylactic decision as a separate, evidence-anchored step rather than a bundled habit.

Before theatre

Optimisation (above) is complete; the immediate pre-theatre tasks are to confirm fasting (clear fluids to two hours, a light meal to six hours — not prolonged starvation, which worsens insulin resistance), give carbohydrate loading where the enhanced-recovery pathway uses it, prescribe the VTE prophylaxis plan, and ensure the antibiotic is available to give at the right moment. Site marking and the consent re-check happen here.

In theatre — the WHO Surgical Safety Checklist

The checklist is the structural safeguard, and you must know its three phases by their triggers:

Its value is not the paper but the team behaviour it forces — naming the team, speaking up, and catching the wrong-site, wrong-antibiotic-timing and retained-swab errors before they happen. The checklist is a communication and culture intervention; ticking boxes without the verbal cross-check is checklist theatre and captures none of the benefit.

The prophylaxis decisions, taken one at a time

Antibiotic prophylaxis follows directly from the infection mechanism. Give it for procedures that breach a colonised surface or carry meaningful infection consequences — hysterectomy (vaginal or abdominal), and procedures entering the bowel or vagina; clean procedures without prosthetic material generally do not need it. What matters most is timing and dose, not drug choice:

• A single dose, intravenously, within 60 minutes before incision, so tissue levels exceed the MIC at the moment of incision (WHO allows up to 120 minutes, accounting for the agent's half-life; aim for ~30–60 minutes for a standard cephalosporin).
• Weight-based dosing — standard fixed doses under-dose the obese patient; the SA and international move is to a higher dose (e.g. 2 g, increasing to 3 g of cefazolin in higher body weight) so that obesity does not silently halve the protection.
• Re-dose intraoperatively for long operations (beyond roughly two antibiotic half-lives, typically ~3–4 hours for cefazolin) or major blood loss, because the tissue concentration falls.
• Do not continue antibiotics postoperatively for prophylaxis — a single dose is non-inferior, and prolongation only drives resistance. The SA EML (Hospital-Level Adult STG, Chapter 11 on surgical prophylaxis) makes single-dose cefazolin the default and frames continuation as a stewardship failure.

VTE prophylaxis follows from Virchow's triad: assess every surgical patient, then deploy mechanical methods (against stasis) and pharmacological methods (against hypercoagulability), matched to the risk tier.

• Risk-assess every patient (a validated tool such as the Department of Health/NICE assessment), weighing the procedure (magnitude, malignancy, pelvic dissection, expected immobility) against bleeding risk.
• Mechanical prophylaxis — anti-embolism stockings or intermittent pneumatic compression — from admission, continued until mobility returns. Mechanical methods are first-line where bleeding risk is high and pharmacological prophylaxis is unsafe.
• Pharmacological prophylaxis — LMWH (e.g. enoxaparin) is the standard agent. For increased-risk abdominal/pelvic (including gynaecological) surgery, NICE NG89 advises adding LMWH for a minimum of 7 days, balanced against bleeding risk and with attention to timing around neuraxial anaesthesia.
• Extended prophylaxis is the gynae-oncology distinction. This is the divergence that most often catches people out: after major cancer surgery in the abdomen or pelvis, prophylaxis is extended to 28 days postoperatively, because malignancy's procoagulant state persists long after the wound has healed. Confusing the benign 7-day plan with the cancer 28-day plan is a classic error — the cancer patient discharged on day 4 still needs three more weeks of LMWH.

Mechanical bowel preparation is the decision where the evidence has reversed received wisdom: do not prep the bowel routinely before gynaecological (or elective colorectal) surgery. It does not reduce anastomotic leak or infection, it dehydrates and distresses the patient, and it is contrary to enhanced-recovery principles. Reserve it for the specific, agreed indication (planned bowel resection where a surgeon requests it), not as a reflex before a hysterectomy.

After theatre — enhanced recovery (ERAS)

Enhanced recovery is the postoperative arm of attenuating the stress response, and its components are deliberate, not optional comforts:

• Avoid prolonged fasting; carbohydrate-load preoperatively — reduces insulin resistance and, in abdominal surgery, length of stay.
• Multimodal, opioid-sparing analgesia — paracetamol, NSAIDs where safe, regional/local-anaesthetic techniques and wound infiltration, so opioids are minimised; this preserves gut function (less ileus, nausea) and mobility.
• Euvolaemia, not over- or under-resuscitation — goal-directed, balanced fluids; fluid overload causes gut oedema and ileus.
• Early feeding — a regular diet within 24 hours after gynae-oncology surgery is recommended; the old "wait for bowel sounds" dogma is gone.
• Early mobilisation — out of bed the day of or after surgery, which directly counters venous stasis and deconditioning.
• Plus prophylactic antiemesis, removal of drains and catheters early, and a clear discharge and follow-up plan.

The ERAS Society's 2019 gynaecologic/oncology guideline packages exactly these elements, and the cumulative effect — shorter stay, fewer complications, faster return of function — comes from applying the bundle, not cherry-picking one item.

Day-case surgery and the SA reality

Much minor and intermediate gynaecological surgery (diagnostic laparoscopy, hysteroscopy, surgical management of miscarriage, sterilisation) is appropriately day-case: select a fit patient (low ASA, adequate social support, reachable in an emergency) and a procedure with predictable recovery and low bleeding risk. In the SA public system, day-case and enhanced-recovery pathways are not only patient-friendly — they are a throughput intervention. Theatre access is the rate-limiting resource; a patient who goes home the same day or on day 1 frees a bed and a slot, and a long elective waiting list is itself a clinical harm (progression of disease, prolonged symptoms). Framing safe efficient perioperative care as a system response to constrained capacity, not a luxury, is the consultant-level point.

Guidelines compared

The major bodies broadly agree on principles but diverge on emphasis and detail; know where, and flag what is recent.

Where they genuinely differ is in the precise duration thresholds (NICE's ≥7-day benign / 28-day cancer split is the most quotable) and in how prescriptive each is about extended prophylaxis — the ERAS and oncology bodies single out advanced ovarian cancer as the archetypal extended-prophylaxis patient. The recent direction of travel (≤5 years) is convergence on single-dose, weight-adjusted antibiotic prophylaxis with no postoperative continuation as a stewardship imperative, and on enhanced recovery and abandoned routine bowel prep as standard rather than experimental. None of these is controversial at the principle level; the precision is in the numbers themselves.

The evidence & the controversy

Three threads are worth being able to argue.

First, the checklist works, but culture is the active ingredient. Haynes' 2009 global cohort showed major complications falling from 11.0% to 7.0% and in-hospital mortality from 1.5% to 0.8% with the 19-item checklist across eight diverse hospitals. Sceptics rightly note that some large later implementations (notably a population-level Ontario rollout) showed no measurable benefit — the lesson is not that the checklist is useless but that mandating the paper without changing team behaviour captures none of the effect. The checklist is a communication and safety-culture tool, not a clerical ritual, and that distinction resolves the "but does it actually work" objection.

Second, antibiotic stewardship is now a live emergency that reshapes prophylaxis. Antimicrobial resistance is a global and acutely South African crisis, and surgical prophylaxis is a large, often-misused share of hospital antibiotic use. The contemporary position — single dose, correctly timed, weight-adjusted, not continued postoperatively — is driven as much by resistance as by SSI evidence: WHO and the SA EML both frame prolonged surgical prophylaxis as a stewardship failure that confers no extra protection. Giving the right prophylaxis once is both better SSI prevention (correct timing matters more than duration) and responsible stewardship; the registrar who reflexively continues a cephalosporin "to be safe" for three postoperative days is harming the next patient on the ward.

Third, enhanced recovery has shifted from innovation to expectation, and the controversy is implementation, not principle. The components are individually evidenced (carbohydrate loading reducing length of stay in abdominal surgery; opioid-sparing analgesia reducing ileus; abandoning routine MBP), and the bundle outperforms à-la-carte adoption. The honest debate is about fidelity and equity: ERAS pathways were validated in well-resourced systems, and the SA challenge is delivering the cheap, high-value elements (don't starve, don't over-fill, mobilise early, single-dose antibiotic, no needless bowel prep) reliably even where the expensive ones (specialist regional analgesia, dedicated ERAS nurses) are scarce. Enhanced recovery is best understood as a largely low-cost intervention well suited to a capacity-constrained service, rather than a first-world luxury.

There is also a quieter consent controversy worth a sentence: the post-Montgomery shift to patient-centred disclosure has, properly, made consent a documented dialogue about material risk and alternatives — and the defensible posture is to welcome that as better practice, not to treat it as a defensive paperwork burden.

Landmark trials & key evidence

A worked number worth carrying: in ENOXACAN II, extending enoxaparin from one week to four cut venographic VTE from 12.0% to 4.8% — an absolute risk reduction of 7.2% (0.120 − 0.048), so the number needed to treat ≈ 1 / 0.072 ≈ 14 women given three extra weeks of a cheap, available LMWH to prevent one VTE after cancer surgery. That single calculation is the whole justification for the 28-day rule, derivable from the trial data rather than asserted as a bare "extend to 28 days."

Worked viva — structuring the answer

A typical stem: "A 62-year-old woman with advanced ovarian cancer is booked for primary debulking surgery. She is obese (BMI 38), anaemic (Hb 9.2 g/dL), and a smoker. Take me through how you would keep her safe perioperatively." A high-scoring answer runs:

1. Optimise and risk-stratify before theatre — "I would correct the anaemia in clinic with intravenous iron rather than plan to transfuse around it, assess functional capacity and cardiac risk, address smoking, and confirm she is fit for major surgery; obesity and malignancy already place her in the highest VTE tier."
2. Consent to the Montgomery standard — "I would discuss the material risks of debulking — bleeding, transfusion, bowel/bladder injury, stoma possibility, VTE, the extent of surgery — and the reasonable alternatives including neoadjuvant chemotherapy, tailored to what matters to her, and document the discussion, not a tick-box."
3. Theatre discipline — "WHO checklist with a genuine verbal time-out; single-dose weight-adjusted antibiotic prophylaxis (3 g cefazolin given within the hour before incision because of her BMI), re-dosed if the case runs long or bleeds heavily; no routine bowel prep."
4. VTE prophylaxis matched to her tier — "Mechanical prophylaxis from admission plus LMWH, and crucially extended to 28 days after discharge because this is major pelvic cancer surgery — ENOXACAN II gives an NNT of about 14 for that extension."
5. Enhanced recovery — "Carbohydrate loading, no prolonged fasting, multimodal opioid-sparing analgesia, euvolaemic fluids, early feeding within 24 hours and early mobilisation — the bundle that blunts the stress response and shortens her stay."
6. The system frame — "In our setting I would deliver the low-cost ERAS elements reliably, plan her follow-up around her access to care, and free the bed promptly, because theatre and bed capacity is itself a clinical resource."

Exam traps & red flags

• Confusing the benign 7-day and cancer 28-day VTE plans. The major-cancer abdominal/pelvic surgery patient needs extended prophylaxis (≈28 days, ENOXACAN II); discharging her on a few days of LMWH like a benign hysterectomy under-treats the highest-risk patient there is.
• Forgetting weight-based antibiotic dosing. A standard fixed dose under-doses the obese woman and silently removes her protection; the obese patient needs the higher (e.g. 3 g cefazolin) dose.
• Wrong antibiotic timing, or continuing it postoperatively. Prophylaxis given after incision misses the decisive window; continuing it for days afterwards adds no benefit and drives resistance — both are stewardship and SSI errors.
• Routine mechanical bowel prep. Prepping the bowel "to be safe" before a hysterectomy is evidence-contrary (no benefit, real harm) and anti-ERAS; reserve it for an agreed bowel-resection indication.
• Consent as a tick-box. Reciting a generic risk list, or consenting in the anaesthetic room minutes before, fails the Montgomery material-risk and dialogue standard and the National Health Act; you must discuss material risks and alternatives and document the conversation.
• Prolonged preoperative fasting. Starving the patient from midnight worsens insulin resistance and is unnecessary — clear fluids to 2 hours, light meal to 6 hours.
• Checklist theatre. Ticking the WHO checklist without a real verbal team cross-check captures none of its benefit; the culture is the intervention.
• Treating ERAS as optional or unaffordable. The high-value elements are cheap; failing to deliver them in a resource-limited service is a missed, low-cost opportunity, not a justified omission.
• Transfusing around anaemia instead of correcting it. Accepting a low preoperative haemoglobin and planning perioperative transfusion, rather than diagnosing and treating the anaemia in clinic, worsens outcomes and wastes blood.
• Mistaking age for frailty. It is frailty, not chronological age, that predicts outcome; a fit older woman should not be denied appropriate surgery, and a frail younger one needs a tailored plan.

Evidence anchors

• Haynes et al. — A Surgical Safety Checklist to Reduce Morbidity and Mortality in a Global Population, N Engl J Med 2009
• Steinberg et al. — Timing of Antimicrobial Prophylaxis and the Risk of Surgical Site Infections (TRAPE), Ann Surg 2009
• Bergqvist et al. — Duration of Prophylaxis against VTE with Enoxaparin after Surgery for Cancer (ENOXACAN II), N Engl J Med 2002
• Güenaga et al. — Mechanical bowel preparation for elective colorectal surgery, Cochrane 2011
• Smith et al. — Preoperative carbohydrate treatment for enhancing recovery after elective surgery, Cochrane 2014
• Nelson et al. — ERAS Society guidelines for perioperative care in gynecologic/oncology, 2019 update, Int J Gynecol Cancer 2019
• NICE NG89 — Venous thromboembolism in over 16s: reducing the risk of hospital-acquired DVT or PE
• NICE NG125 — Surgical site infections: prevention and treatment
• WHO Global Guidelines for the Prevention of Surgical Site Infection
• Montgomery v Lanarkshire Health Board [2015] UKSC 11 — the material-risk standard for informed consent.
• National Health Act 61 of 2003 (South Africa) — statutory informed-consent requirements; HPCSA ethical guidance on informed consent.
• South Africa NDoH Standard Treatment Guidelines & Essential Medicines List, Hospital Level (Adults), 6th ed. 2024 — Chapter 11, Surgical Antibiotic Prophylaxis (single-dose cefazolin, weight-based, antimicrobial-stewardship framing).